In this episode, VTE rate with abemaciclib (uh-bem-uh-cy-clib) higher in real-world setting; Enhertu extends progression-free survival in patient subgroup; FDA grants priority review to elacestrant (ee-las-cess-trant) for metastatic disease; and more. Read the full coverage here: VTE rate with abemaciclib higher in real-world setting among patients with breast cancer Enhertu extends progression-free survival in breast cancer subgroup, topline data show FDA grants priority review to elacestrant for metastatic breast cancer Lack of financial comfort linked to weight gain among young breast cancer survivors Hispanic ethnicity often not reported in breast cancer studies References: Bazan JG, et al. JAMA Oncol. 2022;doi:10.1001/jamaoncol.2022.3527. Press Release Press Release Sella T, et al. Cancer. 2022;doi:10.1002/cncr.34342. Watson NW, et al. Cancer. 2022.doi:10.1002/cncr.34367.

Ver todos los episodios